<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731185</url>
  </required_header>
  <id_info>
    <org_study_id>P03218</org_study_id>
    <nct_id>NCT00731185</nct_id>
  </id_info>
  <brief_title>Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety of Mometasone Furoate Nasal Spray (MFNS) in the Post Surgical Treatment of Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate the effectiveness of mometasone nasal spray in&#xD;
      preventing polyp relapse/symptom worsening in patients after surgical treatment of nasal&#xD;
      polyps. Patients who met Screening eligibility underwent endoscopic sino-nasal surgery (FESS)&#xD;
      on visit 2. Mometasone nasal spray or placebo was started about 2 weeks after surgery and&#xD;
      continued for up to 24 weeks or until relapse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2003</start_date>
  <completion_date type="Actual">September 1, 2005</completion_date>
  <primary_completion_date type="Actual">September 1, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse in polyp score after surgery</measure>
    <time_frame>Assessment for relapse was performed at every study visit (up to 24 weeks of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Signs and symptom scores</measure>
    <time_frame>All study visits (up to 24 weeks of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, peak nasal inspiratory flow, olfaction threshold</measure>
    <time_frame>Measured starting 1 week after treatment up to 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout the whole study after the Screening period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate Nasal Spray (MFNS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate Nasal Spray</intervention_name>
    <description>MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse</description>
    <arm_group_label>Mometasone Furoate Nasal Spray (MFNS)</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 032088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Bilateral nasal polyps&#xD;
&#xD;
          -  Fulfill criteria for polypectomy (be indicated for surgical - FESS - treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polypectomy within the last 6 months&#xD;
&#xD;
          -  Unhealed nasal surgery/trauma&#xD;
&#xD;
          -  &gt;5 previous polypectomies&#xD;
&#xD;
          -  Female of childbearing age who is pregnant, lactating, or not using active&#xD;
             contraceptive methods&#xD;
&#xD;
          -  Nasal infection&#xD;
&#xD;
          -  Pulmonary tuberculosis&#xD;
&#xD;
          -  Cystic fibrosis, glaucoma, clinically significant cardiovascular, pulmonary, renal,&#xD;
             hepatic, metabolic, hematological, or neurological disease&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  Rhinitis medicamentosa (rebound congestion following misuse of nasal decongestants)&#xD;
&#xD;
          -  Known hereditary mucociliary dysfunction&#xD;
&#xD;
          -  Significant nasal structure abnormalities&#xD;
&#xD;
          -  Asthmatic attack within the past 30 days&#xD;
&#xD;
          -  Asthmatic patients requiring &gt;1000 mcg beclomethasone or equivalent&#xD;
&#xD;
          -  Asthmatic patients not stable on corticosteroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional</keyword>
  <keyword>endoscopic</keyword>
  <keyword>sinus</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

